Strides Shasun Gets US Regulator Nod For Anti-Allergy Capsules

New Delhi: Strides Shasun today said it has received approval from the US Food and Drug Administration for cetirizine hydrochloride capsules, used to relieve allergy symptoms.

In a BSE filing, Strides Shasun said, "It has received approval from the US FDA for cetirizine hydrochloride capsules, 10mg (liquid filled capsules OTC)".

The company said the product will be manufactured at its facility in Bengaluru and is ready for launch.

Quoting IRI data, Strides Shasun said the US market for cetirizine hydrochloride capsules is approximately $60 million, with only one other generic player.

Shares of the company were trading 0.16 per cent higher at Rs 1,081.20 on BSE.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)